{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:16:13Z","timestamp":1793373373620,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Herzzentrum G\u00f6ttingen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00406-025-02123-8","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T04:40:05Z","timestamp":1758948005000},"page":"2251-2264","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of a fully automated assay for the measurement of plasma pTau217 and a composite score integrating the ratio A\u03b21-42\/1-40 as biomarkers of Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"276","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8174-9301","authenticated-orcid":false,"given":"Barbara","family":"Morgado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8672-9032","authenticated-orcid":false,"given":"Hans-Wolfgang","family":"Klafki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4199-5468","authenticated-orcid":false,"given":"Chris","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4502-1344","authenticated-orcid":false,"given":"Annik","family":"Steiert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2925-5790","authenticated-orcid":false,"given":"Katharina","family":"Waniek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9225-1493","authenticated-orcid":false,"given":"Ingolf","family":"Lachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8832-3164","authenticated-orcid":false,"given":"Dirk","family":"Osterloh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5484-9710","authenticated-orcid":false,"given":"Hermann","family":"Esselmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5785-9594","authenticated-orcid":false,"given":"Niels","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8896-4328","authenticated-orcid":false,"given":"Johannes","family":"Schuchhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1492-5330","authenticated-orcid":false,"given":"Jens","family":"Wiltfang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,27]]},"reference":[{"key":"2123_CR1","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1126\/science.abi5208","volume":"373","author":"K Blennow","year":"2021","unstructured":"Blennow K (2021) Phenotyping Alzheimer\u2019s disease with blood tests. Science 373:626\u2013628","journal-title":"Science"},{"key":"2123_CR2","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","volume":"28","author":"NJ Ashton","year":"2022","unstructured":"Ashton NJ, Janelidze S, Mattsson-Carlgren N, Binette AP, Strandberg O, Brum WS, Karikari TK, Gonz\u00e1lez-Ortiz F, Di Molfetta G, Meda FJ (2022) Differential roles of a\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring. Nat Med 28:2555\u20132562","journal-title":"Nat Med"},{"key":"2123_CR3","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/ana.25334","volume":"84","author":"IM Verberk","year":"2018","unstructured":"Verberk IM, Slot RE, Verfaillie SC, Heijst H, Prins ND, van Berckel BN, Scheltens P, Teunissen CE, van der Flier WM (2018) Plasma amyloid as prescreener for the earliest a lzheimer pathological changes. Ann Neurol 84:648\u2013658","journal-title":"Ann Neurol"},{"key":"2123_CR4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13195-022-00990-0","volume":"14","author":"A Pichet Binette","year":"2022","unstructured":"Pichet Binette A, Palmqvist S, Bali D, Farrar G, Buckley CJ, Wolk DA, Zetterberg H, Blennow K, Janelidze S, Hansson O (2022) Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer\u2019s dementia in mild cognitive impairment patients. Alzheimers Res Ther 14:46","journal-title":"Alzheimers Res Ther"},{"key":"2123_CR5","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","volume":"27","author":"S Palmqvist","year":"2021","unstructured":"Palmqvist S, Tideman P, Cullen N, Zetterberg H, Blennow K, Initiative AsDN, Dage JL, Stomrud E, Janelidze S, Mattsson-Carlgren N (2021) Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med 27:1034\u20131042","journal-title":"Nat Med"},{"key":"2123_CR6","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1001\/jamaneurol.2022.5272","volume":"80","author":"N Mattsson-Carlgren","year":"2023","unstructured":"Mattsson-Carlgren N, Salvad\u00f3 G, Ashton NJ, Tideman P, Stomrud E, Zetterberg H, Ossenkoppele R, Betthauser TJ, Cody KA, Jonaitis EM (2023) Prediction of longitudinal cognitive decline in preclinical Alzheimer disease using plasma biomarkers. JAMA Neurol 80:360\u2013369","journal-title":"JAMA Neurol"},{"key":"2123_CR7","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, Hansson O, Ho C, Jagust W, McDade E, Molinuevo JL, Okonkwo OC, Pani L, Rafii MS, Scheltens P, Siemers E, Snyder HM, Sperling R, Teunissen CE, Carrillo MC (2024) Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s association workgroup. Alzheimers Dement 20:5143\u20135169","journal-title":"Alzheimers Dement"},{"key":"2123_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack","year":"2013","unstructured":"Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD (2013) Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12:207\u2013216","journal-title":"Lancet Neurol"},{"key":"2123_CR9","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1212\/01.WNL.0000115115.98960.37","volume":"62","author":"M Ingelsson","year":"2004","unstructured":"Ingelsson M, Fukumoto H, Newell K, Growdon J, Hedley-Whyte E, Frosch M, Albert M, Hyman B, Irizarry MJN (2004) Early a\u03b2 accumulation and progressive synaptic loss, gliosis, and tangle formation in ad brain. Neurology 62:925\u2013931","journal-title":"Neurology"},{"key":"2123_CR10","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/nature08538","volume":"461","author":"RJ Perrin","year":"2009","unstructured":"Perrin RJ, Fagan AM, Holtzman DMJN (2009) Multimodal techniques for diagnosis and prognosis of Alzheimer\u2019s disease. Nature 461:916\u2013922","journal-title":"Nature"},{"issue":"1284\u20131298","key":"2123_CR11","volume":"97","author":"C Sato","year":"2018","unstructured":"Sato C, Barth\u00e9lemy NR, Mawuenyega KG, Patterson BW, Gordon BA, Jockel-Balsarotti J, Sullivan M, Crisp MJ, Kasten T, Kirmess KM (2018) Tau kinetics in neurons and the human central nervous system. Neuron 97(1284\u20131298):e1287","journal-title":"Neuron"},{"key":"2123_CR12","doi-asserted-by":"publisher","first-page":"614","DOI":"10.2967\/jnumed.120.245423","volume":"62","author":"VL Villemagne","year":"2021","unstructured":"Villemagne VL, Lopresti BJ, Dor\u00e9 V, Tudorascu D, Ikonomovic MD, Burnham S, Minhas D, Pascoal TA, Mason NS, Snitz B (2021) What is T+? A gordian knot of tracers, thresholds, and topographies. J Nucl Med 62:614\u2013619","journal-title":"J Nucl Med"},{"key":"2123_CR13","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","volume":"26","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy NR, Li Y, Joseph-Mathurin N, Gordon BA, Hassenstab J, Benzinger TL, Buckles V, Fagan AM, Perrin RJ, Goate AM (2020) A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer\u2019s disease. Nat Med 26:398\u2013407","journal-title":"Nat Med"},{"key":"2123_CR14","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamaneurol.2020.4201","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze S, Berron D, Smith R, Strandberg O, Proctor NK, Dage JL, Stomrud E, Palmqvist S, Mattsson-Carlgren N, Hansson O (2021) Associations of plasma phospho-tau217 levels with tau positron emission tomography in early Alzheimer disease. JAMA Neurol 78:149\u2013156","journal-title":"JAMA Neurol"},{"key":"2123_CR15","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz2387","volume":"6","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren N, Andersson E, Janelidze S, Ossenkoppele R, Insel P, Strandberg O, Zetterberg H, Rosen HJ, Rabinovici G, Chai X (2020) A\u03b2 deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in alzheimer\u2019s disease. Sci Adv 6:eaaz2387","journal-title":"Sci Adv"},{"key":"2123_CR16","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s43587-022-00204-0","volume":"2","author":"J Therriault","year":"2022","unstructured":"Therriault J, Pascoal TA, Lussier FZ, Tissot C, Chamoun M, Bezgin G, Servaes S, Benedet AL, Ashton NJ, Karikari TK (2022) Biomarker modeling of Alzheimer\u2019s disease using PET-based Braak staging. Nat Aging 2:526\u2013535","journal-title":"Nat Aging"},{"key":"2123_CR17","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","volume":"80","author":"J Therriault","year":"2023","unstructured":"Therriault J, Vermeiren M, Servaes S, Tissot C, Ashton NJ, Benedet AL, Karikari TK, Lantero-Rodriguez J, Brum WS, Lussier FZ (2023) Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs tau positron emission tomography. JAMA Neurol 80:188\u2013199","journal-title":"JAMA Neurol"},{"key":"2123_CR18","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/alz.12236","volume":"17","author":"TK Karikari","year":"2021","unstructured":"Karikari TK, Emer\u0161i\u010d A, Vrillon A, Lantero-Rodriguez J, Ashton NJ, Kramberger MG, Dumurgier J, Hourregue C, \u010cu\u010dnik S, Brinkmalm G (2021) Head-to-head comparison of clinical performance of csf phospho-tau T181 and T217 biomarkers for Alzheimer\u2019s disease diagnosis. Alzheimers Dement 17:755\u2013767","journal-title":"Alzheimers Dement"},{"key":"2123_CR19","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2023","unstructured":"Janelidze S, Bali D, Ashton NJ, Barth\u00e9lemy NR, Vanbrabant J, Stoops E, Vanmechelen E, He Y, Dolado AO, Triana-Baltzer G (2023) Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain 146:1592\u20131601","journal-title":"Brain"},{"issue":"5","key":"2123_CR20","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/alz.12841","volume":"19","author":"NJ Ashton","year":"2023","unstructured":"Ashton NJ, Puig-Pijoan A, Mil\u00e0-Alom\u00e0 M, Fern\u00e1ndez-Lebrero A, Garc\u00eda-Escobar G, Gonz\u00e1lez-Ortiz F, Kac PR, Brum WS, Benedet AL, Lantero-Rodriguez J, Day TA (2023) Plasma and CSF biomarkers in a memory clinic: head-to-head comparison of phosphorylated tau immunoassays. Alzheimers Dement 19(5):1913\u20131924","journal-title":"Alzheimers Dement"},{"key":"2123_CR21","volume":"14","author":"V Dor\u00e9","year":"2022","unstructured":"Dor\u00e9 V, Doecke JD, Saad ZS, Triana-Baltzer G, Slemmon R, Krishnadas N, Bourgeat P, Huang K, Burnham S, Fowler C (2022) Plasma p217+ tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer\u2019s continuum. Alzheimer\u2019s Dementia: Diagnosis, Assessment Disease Monitoring 14:e12307","journal-title":"Alzheimer's Dementia: Diagnosis, Assessment Disease Monitoring"},{"key":"2123_CR22","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, Su Y, Chen Y, Serrano GE, Leuzy A (2020) Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324:772\u2013781","journal-title":"JAMA"},{"key":"2123_CR23","doi-asserted-by":"publisher","first-page":"e11170","DOI":"10.15252\/emmm.201911170","volume":"11","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist S, Insel PS, Stomrud E, Janelidze S, Zetterberg H, Brix B, Eichenlaub U, Dage JL, Chai X, Blennow KJEmm, (2019) Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in alzheimer\u2019s disease. EMBO Molecular Med 11:e11170","journal-title":"EMBO Molecular Med"},{"key":"2123_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-017-0314-2","volume":"10","author":"F Jessen","year":"2018","unstructured":"Jessen F, Spottke A, Boecker H, Brosseron F, Buerger K, Catak C, Fliessbach K, Franke C, Fuentes M, Heneka MT (2018) Design and first baseline data of the dzne multicenter observational study on predementia alzheimer\u2019s disease (delcode). Alzheimers Res Ther 10:1\u201310","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"2123_CR25","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ (2011) The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7(3):270\u2013279","journal-title":"Alzheimers Dement"},{"key":"2123_CR26","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","volume":"20","author":"B Dubois","year":"2021","unstructured":"Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S, Bejanin A, Bombois S, Epelbaum S, Teichmann MJTLN (2021) Clinical diagnosis of Alzheimer\u2019s disease: recommendations of the international working group. Lancet Neurol 20:484\u2013496","journal-title":"Lancet Neurol"},{"key":"2123_CR27","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jneumeth.2009.06.033","volume":"183","author":"O Calero","year":"2009","unstructured":"Calero O, Hortig\u00fcela R, Bullido MJ, Calero M (2009) Apolipoprotein e genotyping method by real time PCR, a fast and cost-effective alternative to the TaqMan\u00ae and FRET assays. J Neurosci Methods 183:238\u2013240","journal-title":"J Neurosci Methods"},{"key":"2123_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-018-0448-x","volume":"10","author":"H Shahpasand-Kroner","year":"2018","unstructured":"Shahpasand-Kroner H, Klafki H-W, Bauer C, Schuchhardt J, H\u00fcttenrauch M, Stazi M, Bouter C, Wirths O, Vogelgsang J, Wiltfang J, Therapy (2018) A two-step immunoassay for the simultaneous assessment of a\u03b238, a\u03b240 and a\u03b242 in human blood plasma supports the a\u03b242\/a\u03b240 ratio as a promising biomarker candidate of Alzheimer\u2019s disease. Alzheimers Res Ther 10:1\u201314","journal-title":"Alzheimers Res Ther"},{"key":"2123_CR29","doi-asserted-by":"crossref","unstructured":"Morgado B, Klafki H-W, Bauer C, Waniek K, Esselmann H, Wirths O, Hansen N, Lachmann I, Osterloh D, Schuchhardt J (2024) Assessment of immunoprecipitation with subsequent immunoassays for the blood-based diagnosis of alzheimer\u2019s disease. European Archives of Psychiatry and Clinical Neuroscience:1\u201313","DOI":"10.1007\/s00406-023-01751-2"},{"key":"2123_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/alz.079647","volume":"19","author":"M Van dijck","year":"2023","unstructured":"Van dijck M, Dekeyser F, Lambrechts C, Hasumi Y, Van Loo M, Accou F, Sato H, Inaoka D, Nojima H, Degrieck R (2023) Preliminary performance of the lumipulse g ptau 217 plasma prototype assay on plasma samples. Alzheimers Dement 19:e079647","journal-title":"Alzheimers Dement"},{"issue":"8","key":"2123_CR31","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1001\/archneurol.2010.179","volume":"67","author":"G De Meyer","year":"2010","unstructured":"De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, Coart E, Hansson O, Minthon L, Zetterberg H, Blennow K (2010) Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 67(8):949\u2013956","journal-title":"Arch Neurol"},{"issue":"1","key":"2123_CR32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13195-016-0233-7","volume":"9","author":"D Bertens","year":"2017","unstructured":"Bertens D, Tijms BM, Scheltens P, Teunissen CE, Visser PJ (2017) Unbiased estimates of cerebrospinal fluid \u03b2-amyloid 1\u201342 cutoffs in a large memory clinic population. Alzheimers Res Ther 9(1):8","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"2123_CR33","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1373\/clinchem.2017.281055","volume":"64","author":"BM Tijms","year":"2018","unstructured":"Tijms BM, Willemse EA, Zwan MD, Mulder SD, Visser PJ, van Berckel BN, van der Flier WM, Scheltens P, Teunissen CE (2018) Unbiased approach to counteract upward drift in cerebrospinal fluid amyloid-\u03b2 1\u201342 analysis results. Clin Chem 64(3):576\u2013585","journal-title":"Clin Chem"},{"issue":"2","key":"2123_CR34","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/alz.12674","volume":"19","author":"F Jessen","year":"2023","unstructured":"Jessen F, Wolfsgruber S, Kleineindam L, Spottke A, Altenstein S, Bartels C, Berger M, Brosseron F, Daamen M, Dichgans M, Dobisch L (2023) Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers. Alzheimers Dement 19(2):487\u2013497","journal-title":"Alzheimers Dement"},{"key":"2123_CR35","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1080\/01621459.1983.10477973","volume":"78","author":"B Efron","year":"1983","unstructured":"Efron B (1983) Estimating the error rate of a prediction rule: improvement on cross-validation. J Am Stat Assoc 78:316\u2013331","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"2123_CR36","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen CE, Verberk IM, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, van der Flier WM, Mielke MM, Del Campo M (2022) Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol 21(1):66\u201377","journal-title":"Lancet Neurol"},{"key":"2123_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12131","author":"A Keshavan","year":"2021","unstructured":"Keshavan A, Wellington H, Chen Z, Khatun A, Chapman M, Hart M, Cash DM, Coath W, Parker TD, Buchanan SM, Keuss SE (2021) Concordance of CSF measures of Alzheimer\u2019s pathology with amyloid PET status in a preclinical cohort: a comparison of Lumipulse and established immunoassays. Alzheimer\u2019s Dementia: Diagnosis, Assessment Disease Monitoring. https:\/\/doi.org\/10.1002\/dad2.12131","journal-title":"Alzheimer's Dementia: Diagnosis, Assessment Disease Monitoring"},{"issue":"9","key":"2123_CR38","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1002\/acn3.50873","volume":"6","author":"D Alcolea","year":"2019","unstructured":"Alcolea D, Pegueroles J, Munoz L, Camacho V, L\u00f3pez-Mora D, Fern\u00e1ndez-Le\u00f3n A, Le Bastard N, Huyck E, Nadal A, Olmedo V, Sampedro F (2019) Agreement of amyloid PET and CSF biomarkers for Alzheimer\u2019s disease on Lumipulse. Ann Clin Transl Neurol 6(9):1815\u20131824","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"2123_CR39","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13195-019-0550-8","volume":"11","author":"MJ Leit\u00e3o","year":"2021","unstructured":"Leit\u00e3o MJ, Silva-Sp\u00ednola A, Santana I, Olmedo V, Nadal A, Le Bastard N, Baldeiras I (2021) Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer\u2019s disease. Alzheimer\u2019s Res Ther 11(1):91","journal-title":"Alzheimer's Res Ther"},{"issue":"4","key":"2123_CR40","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2217\/bmm.12.49","volume":"6","author":"JW Bartlett","year":"2012","unstructured":"Bartlett JW, Frost C, Mattsson N, Skillb\u00e4ck T, Blennow K, Zetterberg H, Schott JM (2012) Determining cut-points for Alzheimer\u2019s disease biomarkers: statistical issues, methods and challenges. Biomark Med 6(4):391\u2013400","journal-title":"Biomark Med"},{"key":"2123_CR41","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13195-024-01513-9","volume":"16","author":"J Arranz","year":"2024","unstructured":"Arranz J, Zhu N, Rubio-Guerra S, Rodr\u00edguez-Baz \u00cd, Ferrer R, Carmona-Iragui M, Barroeta I, Ill\u00e1n-Gala I, Santos-Santos M, Fortea J (2024) Diagnostic performance of plasma pTau217, pTau181, A\u03b21-42 and A\u03b21-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease. Alzheimers Res Ther 16:139","journal-title":"Alzheimers Res Ther"},{"key":"2123_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105405","volume":"109","author":"A Feizpour","year":"2024","unstructured":"Feizpour A, Doecke JD, Dor\u00e9 V, Krishnadas N, Huang K, Bourgeat P, Laws SM, Fowler C, Robertson J, Mackintosh L (2024) Accurate detection and staging of Alzheimer\u2019s disease by plasma ptau217 on a high throughput immunoassay platform. EBioMedicine 109:105405","journal-title":"EBioMedicine"},{"key":"2123_CR43","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/ana.26891","volume":"95","author":"Y Li","year":"2024","unstructured":"Li Y, Yen D, Hendrix RD, Gordon BA, Dlamini S, Barth\u00e9lemy NR, Aschenbrenner AJ, Henson RL, Herries EM, Volluz K (2024) Timing of biomarker changes in sporadic Alzheimer\u2019s disease in estimated years from symptom onset. Ann Neurol 95:951\u2013965","journal-title":"Ann Neurol"},{"key":"2123_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-022-01071-y","volume":"14","author":"H-W Klafki","year":"2022","unstructured":"Klafki H-W, Vogelgsang J, Manuilova E, Bauer C, Jethwa A, Esselmann H, Jahn-Brodmann A, Osterloh D, Lachmann I, Breitling B (2022) Diagnostic performance of automated plasma amyloid-\u03b2 assays combined with pre-analytical immunoprecipitation. Alzheimers Res Ther 14:1\u201312","journal-title":"Alzheimers Res Ther"},{"key":"2123_CR45","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s43587-020-00003-5","volume":"1","author":"NC Cullen","year":"2021","unstructured":"Cullen NC, Leuzy A, Palmqvist S, Janelidze S, Stomrud E, Pesini P, Sarasa L, Allu\u00e9 JA, Proctor NK, Zetterberg H (2021) Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. Nat Aging 1:114\u2013123","journal-title":"Nat Aging"},{"key":"2123_CR46","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/alz.12395","volume":"18","author":"S Janelidze","year":"2022","unstructured":"Janelidze S, Palmqvist S, Leuzy A, Stomrud E, Verberk IM, Zetterberg H, Ashton NJ, Pesini P, Sarasa L, Allu\u00e9 JA (2022) Detecting amyloid positivity in early Alzheimer\u2019s disease using combinations of plasma A\u03b242\/A\u03b240 and p-tau. Alzheimers Dement 18:283\u2013293","journal-title":"Alzheimers Dement"},{"key":"2123_CR47","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/alz.12751","volume":"19","author":"S Palmqvist","year":"2023","unstructured":"Palmqvist S, Stomrud E, Cullen N, Janelidze S, Manuilova E, Jethwa A, Bittner T, Eichenlaub U, Suridjan I, Kollmorgen G (2023) An accurate fully automated panel of plasma biomarkers for Alzheimer\u2019s disease. Alzheimers Dement 19:1204\u20131215","journal-title":"Alzheimers Dement"},{"key":"2123_CR48","doi-asserted-by":"publisher","first-page":"5531","DOI":"10.1002\/alz.13163","volume":"19","author":"H Huber","year":"2023","unstructured":"Huber H, Ashton NJ, Schieren A, Montoliu-Gaya L, Molfetta GD, Brum WS, Lantero-Rodriguez J, Gr\u00f6tschel L, Stoffel-Wagner B, Coenen M (2023) Levels of Alzheimer\u2019s disease blood biomarkers are altered after food intake\u2014a pilot intervention study in healthy adults. Alzheimers Dement 19:5531\u20135540","journal-title":"Alzheimers Dement"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-025-02123-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-025-02123-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-025-02123-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:00:50Z","timestamp":1786986050000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-025-02123-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,27]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2123"],"URL":"https:\/\/doi.org\/10.1007\/s00406-025-02123-8","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,27]]},"assertion":[{"value":"2 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JW has been an honorary speaker for Actelion, Amgen, Beeijing Yibai Science and Technology Ltd., Janssen Cilag, Med Update GmbH, Pfizer, Roche Pharma, and has been a member of the advisory boards of Abbott, Biogen, Boehringer Ingelheim, Lilly, MSD Sharp & Dohme, and Roche Pharma and receives fees as a consultant for Immungenetics and Roboscreen. JW holds the following patents: PCT\/EP 2011 001724 and PCT\/EP 2015 052945. CB and JS are employees of Microdiscovery GmbH, Berlin, Germany. IL, KW and DO are employees of Roboscreen GmbH, Leipzig, Germany.The scientists at Roboscreen were responsible for the development of an automated processing of the IP for Abeta and Tau as well as for the development of a Tau IP from blood plasma samples. BM, HWK, HE, OW and NH declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The collection and archiving of biological samples and clinical data in strictly pseudonymous form in a local biobank and their use in biomarker research were approved by the ethics committee of the University Goettingen (9\/2\/16). From all participants or their legal representatives written informed consent was obtained prior to the inclusion in the biobank. In detail, before inclusion in the study and removal of biomaterial, all study participants received detailed information and an information leaflet from the study physicians at the Department of Psychiatry and Psychotherapy, University Medical Center G\u00f6ttingen, before signing a written informed consent form. All study participants had MCI or mild dementia, so that they were able to give informed consent. If the ability to consent was not given, a separate informed consent form was also provided for the study participant's legal representative, and the legal representative signed the informed consent form for the study.All procedures involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}